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ABSTRACT
Venture capital investment performance data and performance attribution are not
typically published. Venture investors articulate (and sell to LPs) conflicting strategies;
the popular business literature and culture is rife with rapidly changing beliefs about the
relative attractiveness of healthcare venture subsectors, particularly therapeutics and
devices. To examine these issues in a more rigorous format I developed a dataset of
healthcare venture deals, scored each deal with a new metric ("jb-score"), and assigned
each portfolio company to appropriate subsectors.
This dataset was then used to examine subsector performance, persistence, and fund
strategy attribution (pure vs. mixed healthcare strategies.) Specifically, I found that the
performance characteristics of device and therapeutic (aka biotech or drug) investments
are similar: both subsectors evidence similar jb-scores and firms who invest heavily in
these subsectors show similar levels of persistent overperformance with devices showing
somewhat higher persistence. Firms that focus on one subsector do not perform as well as
firms that follow a more balanced strategy.
Finally, I examine the validity of the jb-score and offer some suggestions for future
improvements.
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I. Introduction
Investing in early stage health-care companies, particularly those that develop drugs and
devices, is a challenging and risky endeavor. Compared with IT startups, healthcare
startups face significant challenges: a heavily regulated industry, long (multi-year to
multi-decade) development and approval timeframes, and tremendous need for capital to
support these long and expensive R&D efforts. Furthermore, the state of scientific
understanding in healthcare (biology, biochemistry, medicine), although growing rapidly,
is still quite far from a thorough understanding and an ability to accurately model and
engineer solutions that carry a high confidence of technical success. Much of the cost of
drug development comes in expensive human clinical trials where, at the end of the day,
what is really going on is hugely expensive trial and error to test if a potential drug does
what it is hoped to do (efficacy) without also doing unexpected, unpredicted, dangerous
things as well (safety.)
To some extent these more extensive risks and costs are mitigated by the large potential
returns for success. A strong patent regime and large potential market sizes make (at least
some) successes well worth their risks. A number of venture capital firms have focused,
either partially or entirely, on healthcare investing. However there is little public data
available on the relative success of these healthcare investors and little data that can shed
light on differing investment strategies of venture firms in the healthcare arena.
In the absence of good data there is much discussion and debate in the industry about
these various strategies. At issue are the relative attractiveness of different healthcare
subsectors (particularly drug and device subsectors), the benefits or drawbacks of firms
diversifying investments across healthcare subsectors or between IT and healthcare, and
varying beliefs in the cyclicality of these subsectors, the opening and closing of "IPO
windows", and growing or shrinking attractiveness of M&A as a viable venture exit.
What makes these questions particularly important is that if venture investors conclude,
for example, that early-stage drug investing is not profitable, then this sector may be
"starved" for investment and potentially important therapies may languish in academic
labs without much chance for advancement. Indeed, the biotech industry often discusses
this "funding gap" - academics can find funding for basic research and later-stage (i.e.
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clinical-stage) drug companies can also find funding but earlier biotech (pre-clinical) is
particularly hard to fund; this funding gap acts as a real barrier to medical progress.
In thinking about some of these questions we can imagine some possible reasons that
might explain (or at least partially justify) some of these beliefs. Drugs require
substantially more money and time than devices to develop; device development requires
different skills (engineering and material science vs. biochemistry and medicinal
chemistry.) FDA approval requirements are also different. These differences may create
environments where investors who specialize may have advantages; expertise and
networks built over time may create information asymmetries and barriers for new
investors to enter competitive investment markets successfully. Reputational and related
advantages may allow early, successful investors to more easily maintain their dominant
positions and thereby receive better dealflow earlier; perhaps stronger human capital
skillsets to help sustain their advantages.
This paper attempts to examine in some detail performance of healthcare venture funds at
the fund and firm level while also looking within funds to examine investment behavior
at the industry sub-sector level. I compare performance of funds that focus on drugs to
those focusing on devices and those who follow a blended strategy. I apply a concept and
methodology from Kaplan and Schoar (2004) to use persistence as a measure of investor
success applied to healthcare funds and subsets of funds that focus on specific subsectors.
Comprehensive data on venture capital fund performance and performance attribution are
difficult to find. Venture firms articulate a wide range of strategies for their funds but it
can be difficult for outside observers (and perhaps potential limited partners) to validate
historical performance of particular strategies. Furthermore, the industry is rife with sets
of evolving beliefs that may or may not reflect the realities of the investment challenges
venture firms face.
In order to perform this analysis I needed to overcome these limitations using publicly
available data. I constructed a measure of deal success ("jb-score") that ranked individual
investment decisions a venture firm/fund makes based on the exit status of the respective
portfolio company. I ranked IPOs and large M&A exits above modest M&A exits, then
undisclosed transaction value M&A exits and finally no documented exit. I calculated
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this measure for every venture investment in the healthcare industry from 1/1/1990-
9/1/2006. I also coded each portfolio company into its appropriate healthcare sub-sector
(biotech/devices/services/IT/diagnostics.) Biotech (sometimes called "drug' investing in
this paper) and device deals represent the vast majority of healthcare deals; HCIT,
diagnostics and services are much less frequently invested in. With this data I was able to
calculate relative fund performance and subsector performance for each fund, as well as
ascertain how much activity each fund has in the various sub-sectors.
Once constructed, this dataset has enabled answering several key questions about the
performance of these funds. Specifically, I was able to demonstrate that the persistence of
outperformance in private equity and VC that Schoar and Kaplan found holds true for
healthcare investors overall and also holds true for drug and device investors;
furthermore, the magnitude of persistence as measured by regression analysis is similar
for drugs and devices. Absolute performance as measured by jb-scores was calculated for
drugs, devices and the other healthcare subsectors showing similar performance for drugs
and devices; better average performance for funds doing many diagnostic deals and
weaker performance for funds doing substantial healthcare IT and service deals.
I also compared "pureplay" drug and device funds to mixed funds and saw significantly
better performance in the mixed funds. Finally, I provide some evidence that the jb-score
is a meaningful, if imperfect, measure of venture performance and offer suggestions on
improving this metric.
There are several possible ways to interpret these results -- that over a reasonably long
period of time drug and device investing offer similar performance characteristics. First
of all in many cases venture firms invest in both sectors and success in either initially
may offer future advantages of deal flow and human capital that benefit both sectors.
Skillset requirements may be similar across both of these subsectors; or perhaps networks
required to be successful (medical and scientific) may overlap significantly. Finally, the
evidence that blended funds outperform pure healthcare funds may be explained by the
ability of blend-style investors to select exit timing across sectors and take advantage of
M&A and IPO market cyclicality, effectively giving blend-style investors more
opportunities for successful exits than pureplay investors.
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II. Motivating Questions and Relevant Literature
A. Popular culture context
In conversations with several of the principals of life science venture capital firms
I heard very different views on investment strategy. In some cases, investors who
had previously spent a great deal of time with early-stage drug investing were
now disillusioned and moving more efforts into device investing and later-stage
drug deals. They would make statements that basically argued that it was
impossible to be successful as a venture investor in drug investing and that device
investing was a better, safer place to "bet." Two quotes illustrate some of these
tendencies:
"We're not going to do any more early stage therapeutics investing"
- Ellen Baron, Partner, Oxford Biosciences
"The VCs are getting tired..." (...with drug investing)
- Dave McLachlan, former CFO, Genzyme
A quick scan of the popular business literature easily identifies many such themes
- are there fundamental changes in the world that successful investment strategies
should take into account? Some quick examples illustrate this clearly - for
example, trends appear to swing between favoring biotech and favoring devices:
"Biotechnology, considered the darling investment sector of the high
rollers in the early 1990s, seems to have fallen by the wayside, and
investors are now wondering what kind of future this sector holds." VC
Journal "Why Tech VCs Have Left Biotech" 8/1/99
"A healthy increase in venture-capital funding of medical-device
companies has helped lift overall investments in life-sciences industries,
even as biotechnology deals have tailed off." Peter Loftus 2/3/06 WSJ
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Other articles question whether there are substantive differences in the overall risk
profile of device investing when compared to drug investing, as the following
quote illustrates:
"Medical device investing has been the "Steady Eddie" of venture capital;
and also it's Rodney Dangerfield. On Sand Hill Road, especially in the
heady Internet days of the late 1990s, medical device entrepreneurs could
hardly get a meeting, never mind respect. Many top-tier VCs either de-
emphasized or completely shut the door on life science investing. Today,
we realize that information technology (IT) and biotech valuations fall as
fast as they rise, and those seasoned, rock-solid medical device
entrepreneurs who've been waiting in the lobby are looking better by the
day." VC Journal "TechTalk: Hitting Singles and Doubles With Medical
Technology" 12/1/2002
The following illustrates questions regarding the benefits of funds that focus on
subsectors versus diversify across them:
"The era of the generalist venture capitalist is over. Specialized funds are a
logical extension of the continued evolution of both health-care and
information technology investing. Not everyone can be an expert in every
subject." VCJ 8//1/99 "Why Tech VCs Have Left Biotech"
What I take away from these popular business culture "datapoints" are a number
of questions about investment strategy and performance:
* Is there a clear advantage in drugs or device investing?
* Do pure-play drug or device investors perform better than blended funds?
* Do these answers change over time in a cyclical fashion, perhaps correlated to
overall market conditions?
* To what extent does casual conversation and popular culture reflect the data-
supported realities of fund behavior and performance?
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B. Academic Literature on Venture Capital Performance in Life Science
Sub-sectors
Much of the limited academic work on the venture capital business tends to focus
on the overall industry (or even includes the broader set of private equity firms
with venture capital.) Due to the paucity of publicly available research and fund
reticence to share investment strategies, research is hard to perform.
Although there is relatively little direct research reported in the literature on
venture capital performance of life science sub-sectors, the following three
articles address relevant topics in venture capital performance and use methods
that have applicability in this area.
Gompers, Kovner, Lerner, Scharfstein 2005 (Gompers et al.)
Gompers et al. examine patterns of venture capital investments and
performance and their relationship to public market (IPO) patterns. They
use similar methods to those used in this paper to both organize a dataset
of venture investments into 9 industries (one of which is healthcare) and to
score the relative success of investment outcomes in a binary fashion
(M&A or IPO = success; otherwise = failure).
Gompers et al. show that industry-experienced venture investors increase
their rate of investing in that industry in response to increased IPO activity
in that industry and do not suffer performance penalties for this change in
investment behavior. They are trying to disentangle rational investment
behavior based on market signals (IPO rates) vs. irrational (or at least
inefficient allocation of capital) investment choices that demonstrate
"herd" behavior.
Gompers' results bolster the idea that experienced/successful healthcare
blended-fund investors who invest in both drug and device deals may be
able to take advantage of IPO windows rationally; however his analysis
leaves open a number of questions.
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Because their industry groupings are fairly broad (i.e. the authors do not
separate medical devices vs. biotechnology) they conflate subsector
performance that might be negatively correlated. In addition, their
measure of success can be criticized because by scoring all M&A
transactions as a success they risk over-counting successful exits. In many
cases (and particularly when M&A transaction values are non-disclosed)
M&A transactions are not successful exists for venture investors and may
not return much (if any) capital to the venture partnership. In our analysis
below, we use a ranked scoring system to rank M&A exists on transaction
size and only score undisclosed transactions as marginally better than no
transaction at all in an attempt to more accurately characterize venture
outcomes of M&A transactions.
Kaplan & Schoar, 2004
Kaplan & Schoar demonstrated persistence in private equity fund
performance - a key measure of long-term investment success that is not
apparent in public mutual fund performance. They dismissed selection
bias, risk differences, and industry differences as possible explanations
and instead argue that differences in partner skill, deal flow access, better
deal terms, and access better management account for this persistence in
performance. One key question left unanswered is what accounts for first
fund success - one could easily argue that with a strong first-fund track
record, venture firms can more easily attract all of the human and deal
resources identified by Kaplan & Schoar and thereby maintain their
performance advantages over time. However it is equally plausible that
initial fund success is a random (if once achieved thereafter sustainable)
event that occurs before differentiating resources are acquired by the
venture firm.
Kaplan & Schoar's argument lends credence to the idea that successful
venture investing is based on skill and related resources vs. random luck.
This paper applies this methodology to healthcare subsectors and shows
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that skill continues to play a role in investment success through
persistence of fund outperformance; and that the quantitative amount of
persistence is similar for drugs and devices.
Kaplan & Schoar, like Gompers et al above, also use broad industry
classifications and do not divide healthcare into subsectors which could
play an important role in performance attribution. Choices of specific
subsectors as well as subsector specialization could both be possible
source of performance attribution and this paper attempts to explore this
line of inquiry.
Lerner, 1994
In this paper, Josh Lerner discussed the decision for venture firms to take
biotechnology portfolio companies public. He distinguishes the behavior
of less- and more-experienced venture investors in taking their portfolio
companies public at times at or near peaks public markets (measured by an
index he constructs of public biotech companies and proxies) and
demonstrates that more seasoned investors are "particularly proficient at
taking companies public at market peaks."
This paper provides some of the possible underlying reasons why there is
persistence of overperformance in venture capital and points directly to
experience level of investors and their ability to achieve successful exits as
critical expanatory factors in persistence of overperformance.
Of particular note in this paper is his methodology in constructing his
datasets. For example, he uses the age of the oldest VC fund in a company
as a proxy for experience. It would be interesting to apply his approach
and compare device vs. drug investing to see if the patterns he finds in
drug (biotech) investing hold true in devices, where development cycles
are much shorter, capital requirements are smaller, and historically there
has been a more robust M&A market for these firms to exit successfully.
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III. Data - Sources, Analysis, Methodology
A. Data Sources:
To develop the dataset used in this study the following sources of data were used:
* Thompson Financial SDC Platinum downloads: rounds, funds, firms, portcos
(no return data at the fund level): http://www.thomsonib.com/sp.asp. This
source is made available to all MIT students through the Dewey Business
Library.
* Private Equity Intelligence (fund return info but only for -1/3 of HC funds; no
round/investment info): http://ww-w.prequin.com/. This is a costly database; I
contacted the owners of the firm and requested access as a form of
sponsorship with was granted for a 30 day period to enable me to download a
"snapshot" of PEI's data this summer.
* Jay R. Ritter's IPO data: http://bear.cba.ufl.edu/ritter/ipodata.htm, Cordell
Professor of Finance at the University of Florida. This data is publicly and
freely available on Ritter's website.
B. Methods:
1. Overall Strategy and Limitations
Evaluating venture capital firm and fund performance, and attempting to relate
fund performance to investment strategy, is challenged by limitations in available
data. Thompson's SDC data does provide round-level investment information.
This effectively tells us, for every round that a venture firm/fund participates in,
what type of company received the investment, how many investors participated,
and the total size of the round. However we cannot consistently find the allocation
of the round to the various funds participating and therefore need to make several
assumptions to perform subsector analysis and performance attribution. We do
not know the capitalization structure of portfolio companies and the
corresponding % holdings of the investors.
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PEI sells a regularly updated dataset of fund-level performance statistics (and was
willing to provide this data for this study as a sponsor.) However, of the funds we
identified with significant investments in healthcare, only about 30% were found
in the PEI dataset.
Additional exit information is available in Thompson's SDC Platinum. We can
identify every portfolio company's exit data if an exit occurred. Specifically, in
the case of an IPO we have the date and financial characteristics of the IPO. With
M&A exits in some cases the deal value is disclosed, but in many cases it is not.
Therefore we need to make a number of simplifying assumptions in order to carry
out this analysis which can introduce error and noise into our datasets:
* We assume that in every round, all investors participate equally. Although
this clearly does not reflect the reality of investments, round distributions
are not public. Funds that have small "sidecar" entrepreneur funds that co-
invest with main funds may lead to overcounting subsector participation
for particular firms; given the size of the dataset I suspect that such effects
will be similar across subsectors and not introduce subsector-favoring bias
to the following analysis.
* We assume that for most undisclosed M&A exits acquired by public
companies, the value of the transaction must be low enough to be not
meaningful to the acquirer, and therefore not a strongly successful exit for
the investors. There may be a small number of cases on an acquisition by a
very large acquirer that is undisclosed but still large enough to be a
success for the venture investors. In addition, at times a later investor may
invest at a time of desperation, cram down previous investors, and be the
only investor to see a successful exit upon a sale. Due to the lack of
detailed exit information I cannot overcome these limitations but do not
believe they are numerous enough to affect the conclusions; and in any
case I believe this bias is a better one to incur than to make the opposite
assumption (as per Gompers et al 2005) where the authors count every
M&A exit as a success independent of valuation amount or disclosure
status.
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* We developed a scoring algorithm (described below) that scores every
"round" that a fund participates in based on the assumed return from the
exit (if any.)
* We scored every separate investment into a portfolio company by a fund
separately and gave each "bet" equal weighting. If a fund made multiple
investments in a single portfolio company each investment was score
independently, representing the idea that a fund makes an independent
decision at each round, and can always decide to stop participating in
future rounds. (Ideally, it would probably be more accurate to weight
follow-on rounds somewhat lower than initial rounds in a future revision
of the jb-score.)
In a later section of this paper this measure is evaluated and several suggestions
are made regarding possible improvements to this methodology for future study.
2. Building the dataset
On 10/22/2006 I downloaded 49,469 VC investment rounds from SDC Platinum
with round dates between 1/1/1990 and 9/1/2006 in the healthcare industry sector.
(see appendix 1 for industry code search criteria) Each round included data on the
investor fund & firm, date, total round amount (note: individual fund allocation of
the round was not available), portfolio company name & industry and other
descriptive information. I developed a lookup table to code each rounds' portfolio
company into healthcare industry sub-sectors (biotech, devices, healthcare IT,
heathcare services, diagnostics) - See Appendix 2 for this table.
SDC data also includes portfolio company IPO data and amount (if any) and
acquisition dates and value (if any.) Each portfolio company was then scored on
its exit as follows:
Behrens, Page 15 of 32
Exit Score
IPO 4
M&A >$100m 4
M&A <= $100m 3
M&A < $50m 2
M&A undisclosed 1
No exit 0
Each of the 49,469 rounds was then scored based on the exit score of its
corresponding portfolio company (0-4.) Totals were calculated for each venture
capital fund for all of that funds deals, as well as subtotals for each HC industry
sub-sector (biotech, devices, etc...) Total numbers of rounds each fund
participated in were counted. A "jb-score" ("Jeff s VC performance score") was
calculated for each fund for each HC subsector and HC investments overall by
dividing the total scores by the number of rounds that firm participated in.
These jb-scores range from 0 to a "perfect" 4.
To examine cyclical effects I calculated average jb-scores for each year for all
healthcare deals and then used these annual averages to normalize jb-scores for
each fund in each subsector and in HC overall.
In each healthcare sub-sector (biotech, devices, etc...) funds with >4, 5 or 9
rounds (depending on the total number of funds in that subsector) were ranked
and assigned to quintiles (quartiles in the case of healthcare diagnostics and
healthcare IT.) This was done for both raw and normalized jb-scores.
Transition matrices were generated for each subsector and healthcare overall in
the following format. These matrices score firms that have multiple funds over
time with fund N along the vertical and fund N+ 1 along the horizontal. This
provides strong evidence of persistence of overperformance when the
percentages along the diagonal (1 ->1 for example) are much higher than a
random distribution which would be -20%.
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biotech_quint
1 2 3 4 5
1 24 7 1 2 1
2 12 17 7 4 1
3 5 16 21 4 0
41 5 10 14 10 5
5 2 8 8 8 7
biotech_quint_norm
1 2 3 4 5
1 19 9 4 2 5
2 13 15 13 7 3
3 10 12 11 8 3
4 4 10 10 6 7
5 4 2 5 6 11
1 2 3 4 5
1 68.6% 20.0% 2.9% 5.7% 2.9%
2 29.3% 41.5% 17.1% 9.8% 2.4%
3 10.9% 34.8% 45.7% 8.7% 0.0%
4 11.4% 22.7% 31.8% 22.7% 11.4%
5 6.1% 24.2% 24.2% 24.2% 21.2%
1 2 3 4 5
1 48.7% 23.1% 10.3% 5.1% 12.8%
2 25.5% 29.4% 25.5% 13.7% 5.9%
3 22.7% 27.3% 25.0% 18.2% 6.8%
4 10.8% 27.0%27.0% 16.2% 18.9%
5 14.3% 7.1% 17.9% 21.4% 39.3%
Finally, regressions were performed with Microsoft Excel's LINEST function
for each subsector - regressing fund N+1 as the "Y" variable to fund N as the X.
This was done for both raw and normalized jb-scores. A 2-variable regression of
fund N+1 to both fund N and the year 3-6 moving average count of IPOs (from
Ritter) was done to look for the role of cyclical effects.
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C. Descriptive Statistics:
The dataset was downloaded from SDC Platinum via MIT's Dewey Library. I
downloaded all healthcare venture capital investments from / 1/1990-9/1/2006
(appendix 1 lists the industry codes used to identify these deals) and coded
investments by the industry and subsector of each respective portfolio company
(appendix 2 shows the coding methodology) which incorporated 1076 venture funds
and 6894 portfolio companies. In Chart I below, 935 funds made biotech investments
and 1001 funds made device investments. These two groups of funds have very
similar "jb-scores" and similar volatility of the jb-score which implies that the
performance of funds in these sub-sectors does nor differ substantially during the time
period measured in this dataset. Diagnostics does appear to have both a much smaller
number of funds investing in the sub-sector and a higher average jb-score (1.39) and
more volatility than biotech and devices. Services and HC appear to perform less less
than biotech and devices overall.
Chart 1: Descriptive Statistics
Number of funds
Average j-score
Average normalized i-score
Total rounds
Total j-score
Total calculated j-scorelrounds
935
1.18
0.38
9,207
10,852
1.18
STD
1.10
1.03
STD
1.07
0.95
1001
1.22
0.32
10,194
12,953
1.27
1076
1.11
0.24
26,981
31,653
1.17
257
0.94
-0.14
2,788
2,693
0.97
(note: number of funds do not total as many funds have substantial investment
activity across multiple subsectors.)
Although most of the analysis in this paper is performed at the venture capital fund
level, it was interesting to look at the source data at the portfolio company level. The
following chart calculates (in the last column) the number of companies funded per
successful exit (M&A with reported valuation >$100m or an IPO) and a notable
difference is seen between subsectors with biotech and device once again being the
strongest areas (and very close) wereas services and hcit appear to be the most "risky"
companies from the perspective of likelihood of a successful exit.
178
1.39
0.35
1,269
1,891
1.49
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ServicesBiotech
STD
1.08
0.91
Device
STD
1.11
0.93
,,,,,
Diagnostics
STD
1.48
1.3
C
r
HCIT
103
1.00
0.04
818
821
1.00
ALL HC
STD
0.93
0.74
Chart 2: Companies per exit
Num Cos M&A IPO total colexit
biotech 2122 40 179 219 9.7
device 2300 53 171 224 10.3
diagnostics 537 9 32 41 13.1
services 1340 42 59 101 13.3
hcit 595 17 22 39 15.3
I performed a similar analysis at the company level to examine $ invested in portfolio
companies and compared this total amount of investment to the number of successful
exits to determine the average "cost" to a successful exit.
Chart 3: $/Exit
$/Exit (1000s)
$300,000
•r$)n nnn0
$200,000
$150,000
$100,000
$50,000$50,0 0 i:i:!'::?~:i;i:
D............ ....... .... ........... ........ . ....... .. .. 
•iliii
.... ....... .
...........................  . . .. ... . ......... • ? . . ... . . ........ . .. .. .
HCIT Biotech Devices HC Services Diagnostics
I then examined the number of investments made by venture firms in each sector,
where an investment was defined as each time a firm invests money in a round. (So a
single round with multiple investors generates multiple investments.) This counting
of individual investment decisions (or "bets") is also the methodology used in
quantifying the investment activity level of venture funds in the various sub-sectors of
heathcare. Chart 4, below, show the number of investments per successful exit in each
subsector.
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Chart 4: Investments/Exit
Investments/Exit
HCIT Diagnostics Devces Biotech HC Services
Finally, I examined investment fund strategies relating to the fund investment
composition mix. Life sciences venture funds follow a subsector strategy - and along
with selecting one or more subsectors, a firm can choose to follow a more "pure"
strategy or one where it balances investments across multiple subsectors.
This chart below compares performance of mixed funds vs. biotech and device
specialty funds. I used actual investment history as the criteria to define fund strategy
- if a fund invested in 8 or more rounds in both devices and biotech (and had >75% of
its total rounds in these areas) then I defined it as a mixed strategy; I defined pure
strategy as >60% of rounds falling into one of the subsectors.
The results of this analysis demonstrate a strong benefit in a mixed strategy with a
very strong improvement in average Jb-scores. Biotech-pure strategies provide the
poorest returns; and the variance of the mixed strategy is also the lowest on a relative
basis.
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Chart 5: Comparing pure vs. mixed subsector strategies
AVG STD Num Notes
mixed fund (all) 1.20 0.85 61 1,2
pure bio >8 rounds 0.76 0.66 74 1,3
pure device >9 round. 0.94 0.83 38 1,4
1 j-scores for ALL rounds fund invested in
2 >75% of rounds are biotech or device and >8 rounds biotech and device
3 >60% rounds are biotech
4 >60% rounds are device
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D. Persistence/Regressions:
Kaplan and Schoar (2004) focus on persistence of overperformance as a key
signal of investor skill in determining long-term firm performance. I was
interested in using this measure to ask a slightly different question - if we
examine persistence across different subsectors of health-care investing, do we
see meaningful differences in persistence; and if we do, perhaps we can interpret
this as evidence in the nature of the investment thesis in that specific subsector.
By combining evidence on persistence with the above identified statistics on
overall sub-sector specific fund performance in the descriptive statistics, I hoped
to be able to rationally, and in an evidenced-based manner, compare investment
thesis across healthcare subsectors.
I performed three regressions for each healthcare industry subsector. "Raw"
regresses jb-scores for fund n+1 to fund n. "Norm" regresses the normalized jb-
scores for fund n+1 to fund n (where normalization is as above - subtracting
average annual healthcare jb-scores from each value.) "Raw + IPO yr" regresses
fund n+l1 to 2 possible explanatory variables - the average IPO count for the year
(from Ritter, a moving average of years 3-6 offset) and fund n. This third
regression is a check to see to what extent subsector performance is explained by
overall industry performance and serves as an alternate method to examine this
from examining the normalized regressions.
Some of the key observations in the "raw" data are that in all subsectors we see
strong evidence of persistence - the larger the coefficient the stronger the
persistence effect. Standard errors are appropriately low for all subsectors but
healthcare IT to provide confidence in these measures. We see a fairly strong
difference in the persistence measure for biotech to devices (.23 to .44) which is
weakened considerably when looking at normalized numbers (.18 to .23). When
regressed to the IPO count as well as to the raw fund performance this difference
in effect almost disappears (.16 to .17).
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Chart 6: Regressions
Coefficient
Std err
Raw R^2
F-val
Coefficient
Std err
Norm R^2
F-val
Coefficient
Std err
Raw + Coefficient
IPO yr Std err
R^2
F-val
biotech device diag hcit services all hc
0.23 0.44 0.51 0.23 0.85 0.52
0.05 0.06 0.13 0.29 0.27 0.04
0.07 0.20 0.24 0.04 0.33 0.27
18.20 54.82 15.55 0.64 23.92 189.47
0.18 0.23 0.33 0.18 0.29 0.29
0.05 0.06 0.13 0.27 0.09 0.04
0.06 0.06 0.13 0.03 0.09 0.10
14.69 13.63 6.89 0.45 9.82 54.47
0.32 1.04 1.54 0.29 0.85 0.82
0.16 0.17 0.47 0.96 0.27 0.09
0.16 0.20 0.30 0.20 0.34 0.29
0.06 0.07 0.13 0.31 0.10 0.04
0.08 0.32 0.39 0.04 0.33 0.36
11.20 51.19 14.86 0.34 23.92 147.88
As a check to examine to possible role public market performance (in particular,
new IPOs) might drive some of the performance of healthcare venture investing, I
regressed biotech and device performance to the number of IPOs/year from Ritter.
As before, for IPO/year I take the first investment date of the fund to define
vintage year and then look at the IPOs 3-6 years out to get a moving average. This
of course shows no correlation; i.e. annual IPO performance is not predictive of
biotech and device performance.
Chart 7: Subsector raw Jb-scores to IPO count regressions
biotech device
Coeff 0.00 0.00
Std Err 0.00 0.00
RA2 0.12 0.23
F-value 26.21 55.43
A somewhat more intuitive way to visualize this data, also used in Kaplan and
Schoar (2004), is the construction of transition matrices. To construct a transition
matrix I grouped funds into quintiles (quartiles for diagnostics and HCIT due to
the paucity of funds doing a meaningful number of transactions.) I then looked at
fund n to fund n+1 transitions (i.e. how often a fund n was in the 1st quintile was
followed by a fund n+ 1 that was also in the 1 st quintile.)
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In the charts below I shaded matrix elements along the diagonal that are well
above expected values from a random distribution. What is particularly striking is
that we see strong persistence in the better-performing funds (1 st & 2"nd quintiles)
with much weaker persistence in the poorer-performing funds. I suspect this may
be due to survivorship bias (the weakest funds have trouble raising follow-on
funds.)
Chart 8: Transition matrices
Transition Matrix/Raw
1 2 3 4 5
1 68.6% 20.0% 2.9% 5.7% 2.9%
2 29.3% 41.5% 17.1% 9.8% 2.4%
3 10.9% 34.8% 45.7% 8.7% 0.0%
4 11.4% 22.7% 31.8% 22.7% 11.4%1
5 6.1% 24.2% 24.2% 24.2% 21.2%
1 2 3 4 5
1 48.4% 35.5% 3.2% 6.5% 6.5%
2 38.1% 28.6% 26.2% 7.1% 0.0%
3 25.6% 25.6% 25.6% 18.6% 4.7%
4 14.3% 5.7% 54.3% 17.1% 8.6%
5 2.9% 17.6% 38.2% 8.8% 32.4%
1 2 3 4
1 57% 29% 0% 14%
2 17% 67% 17% 0%
3 0% 0% 50% 50%
4 0% 0% 0% 100%
1 2 3 4
1 0.0% 100.0% 0.0% 0.0%
2 0.0% 100.0% 0.0% 0.0%
3 66.7% 0.0% 33.3% 0.0%
4 66.7% 0.0% 0.0% 33.3%
1 2 3 4 5
1 57.1% 14.3% 21.4% 0.0% 7.1%
2 29.4% 52.9% 17.6% 0.0% 0.0%
3 18.8% 25.0% 18.8% 25.0% 12.5%
4 0.0% 19.0% 19.0% 57.1% 4.8%
5 12.5% 25.0% 25.0% 12.5% 25.0%
Transition Matrix/Normalized
1 2 3 4 5
1 48.7% 23.1% 10.3% 5.1% 12.8%
2 25.5% 29.4% 25.5% 13.7% 5.9%3 22.7% 27.3% 25.0% 18.2% 6.8%
4 10.8% 27.0% 27.0% 16.2% 18.9%
5 14.3% 7.1% 17.9% 21.4% 39.3%
1 2 3 4 5
1 35.1% 27.0% 18.9% 5.4% 13.5%
2 28.6% 35.7% 11.9% 11.9% 11.9%
3 8.6% 20.0% 37.1% 17.1% 17.1%
4 14.9% 17.0% 27.7% 23.4% 17.0%
5 29.2% 16.7% 20.8% 0.0% 33.3%
1 2 3 4
1 50.0% 33.3% 0.0% 16.7%
2 22.2% 44.4% 11.1% 22.2%
3 0.0% 0.0% 83.3% 16.7%
4 0.0% 0.0% 0.0% 100.0%
1 2 3 4
1 50.0% 50.0% 0.0% 0.0%
2 0.0% 100.0% 0.0% 0.0%
3 40.0% 20.0% 20.0% 20.0%
4 100.0% 0.0% 0.0% 0.0%
1 2 3 4 5
1 25.0% 33.3% 25.0% 16.7% 0.0%
2 25.0% 35.0% 15.0% 15.0% 10.0%
3 17.4% 21.7% 26.1% 26.1% 8.7%
4 15.4% 23.1% 7.7% 30.8% 23.1%
5 12.5% 12.5% 0.0% 12.5% 62.5%
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HCIT
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IV. jb-score Justification, Validation and Possible Improvements
As was discussed in the methods section, above, the Jb-score is a calculated measure of
venture investment performance at the portfolio company level. The construction is to
score every "bet" a venture fund makes in a company round with a number from 0 to 4.
This has the advantage of enabling dissection of fund performance to the individual
portfolio company level or any rational grouping of portfolio companies. This paper
primarily groups portfolio companies based on industry sector and subsector; this
analytical method would support other grouping that could include other factors (stage of
investment, round #, size or rounds, dates of rounds, etc...)
I had to use this measure (similar to Lerner's methology in his 1994 paper) as return data
is not available at the portfolio company level. PEI provides fund IRRs but only has
sparse coverage of funds that focus on health care venture investing. Furthermore, by
being able to relate Jb-score performance measures to number of investments in
subsectors we can rationally filter out small numbers of investments in a particular
subsector and focus on where venture funds/firms actually invest compared to where they
say they invest.
To validate this method I looked at two different statistical tests. First, I examined the
correlation of the jb-score to Ritter's IPO counts. I first examined correlations for all HC
funds and all funds by vintage year (defined by the year of the first investment of the
fund). As venture performance is driven by exits which typically occur several years after
the vintage year of the fund, I examined offsetting the IPO count average by 0-8 years
and found the best correlations between 3-4 years (.57 to .63). By calculating a moving
average of years 3-6 offset, the correlations rose to .63 and .66; a strong correlation and
good evidence that the jb-score is capturing meaningful performance data for individuals
funds (under the assumption that venture fund performance is correlated to IPOs.)
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Chart 9: Ritter IPO Counts to Jb-score Correlations
Ritter IPO Counts
offset HC ALL
yr 3-6 av
Secondly, I obtained venture capital benchmark performance data from SDC platinum by
year and calculated a correlation between these benchmarks and the jb-score for both
healthcare and all venture funds. The results here are not quite as strong as the Ritter
correlations but are still above .5.
Chart 10: Testing the jb-score to HC and all VC
0.5124 corr HC to VC
0.5145 corr all to VC
These results give some direction to possible future improvements in the jb-score.
Given the better correlations with Ritter's IPO data than with venture capital
performance benchmarks we may be over-valuing IPOs as successful exits and could
look at IPO valuations to more carefully calculate the jb-score as we do with M&A
transactions (i.e. score post-money valuations >$200m as 4, >$100m as 3, etc...) A
number of different algorithms could be developed and then tested against VC
benchmarks and Ritter's IPO data to identify the best algorithm for refining the jb-
score.
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V. Conclusions
This thesis explores venture capital investment performance in healthcare and healthcare
subsectors including therapeutics and devices. I constructed a dataset of healthcare
venture capital investment transactions and coded these with industry subsector and a
measure of investment outcome ('"jb-score") that scores IPO and M&A exits. Totals for
number of transactions in each subsector and corresponding total jb-scores were
calculated for each venture capital fund. The dataset was then analyzed to measure
persistence of overperformance of funds that invest in various subsectors and this amount
of persistence was compared across sub-sectors. As in Kaplan and Schoar (2004), overall
healthcare as well as therapeutics and device investors demonstrate persistence in
overperformance; with strongest overperformance in the device subsector. Average jb-
scores were compared across subsectors to give a measure of overall success in
investments in each subsector; variance is similar across subsectors except for healthcare
IT where variance is much larger than the other subsectors. Additional measures were
calculated that include # of portfolio companies per successful exit, $ invested per
successful exit and investments per successful exit to further explore differential
investment performance of healthcare subsectors.
Across all of these analyses there is little different in the behavior of device and
therapeutics beyond a slightly stronger persistence signal mentioned above. It appears
that over the time period examined (1990-2006) the long-term performance of these
subsectors is quite similar. Furthermore, it appears that funds that invest in both sectors
perform better than focused funds that invest more than 60% of the time in a single
subsector.
The jb-score's validity was explored through a series of regressions against annual IPO
counts and annual benchmark venture capital performance; the jb-score appears to
correlate well with these benchmarks providing a strong validation for this constructed
measure.
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Appendix 1: SDC health care investments industry search criteria
2820 Medical/Health
2825 Scientific Products
2840 Medical/Health Services
2845 Scientific
2860 Medical/Health Info/Content
2865 Scientific Info/Content
4111 In Vitro Monoclonal Antibody Diagnostics
4112 In Vivo Monoclonal Antibody Diagnostics/Imaging
4113 DNA/RNA Probes
4119 Other Medical Diagnostic Biotechnology
4121 Therapeutic Monoclonal Antibodies
4122 Immune Response Effectors (interferons, vaccinations)
4123 Other Therapeutic Proteins (incl. hormones)
4129 Other Therapeutic Biotechnology
4130 Genetic Engineering
4311 Biotech Related Fine Chemicals (NOT Pharmaceu
4312 Biotech Related Commodity Chemicals
4319 Other Biochemical Products
4321 Biotech Related Food Enzymes and Cultures
4322 Biotech Related Food Diagnostics
4329 Other Biotech Processes for Food Industrial Products
4525 Biotech laser and optronic applications
5121 X-Rays
5122 CAT Scanning
5123 Ultra Sound Imaging
5124 Nuclear Imaging
5125 Other Medical Imaging
5221 Surgical lasers (including laser delivery fib
5412 Long Term Care/Home Care/Elder Care
5414 Dependent Care (child care/assisted living
2735 Medical/Health Software
2741 Scientific Software
3710 Chromatographs & Related Laboratory Equipment
3720 Other Measuring Devices
3799 Other Analytical & Scientific Instrumentation
4110 Medical Diagnostic Biotechnology Products
4120 Therapeutic Biotechnology Products
4210 Genetically Engineered Plants
4220 Genetic. Eng. Microorganisms to raise plant yield
4230 Other Plant Related Biotechnology
4240 Biotech Related Animal Health & Nutrition Products
4250 Genetically Engineered Animals
4290 Other Animal Related Biotechnology
4310 Biochemical Products
4320 Biotech Processes for Food Industrial Applications
4330 Biotech Processes for Pollution/Toxic Waste Contrl
4340 Biotech Processes for Enhanced Oil Recovery/Mining
4390 Other Industrial Biotechnology
4410 Biosensors for Medical Diagnostic Applications
4420 Biosensors for Industrial Applications
4490 Other Biosensors
4510 Biotech Related Analytical Instruments & Apparatus
4520 Biotech Related Production Equipment
4599 Other Biotech Research & Production Equipment
4610 Pure & Contract Biotechnology Research
4699 Other Biotechnology Services
5110 Diagnostic Services
5120 Medical Imaging
5130 Diagnostic Test Products & Equipment
5140 Other Medical Diagnostics
5210 Therapeutic Services
5220 Surgical Instrumentation & Equipment
5230 Pacemakers & Artificial Organs
5240 Drug Delivery & Other Equipment
5299 Other Therapeutic (including defibrillators)
5310 Disposable Medical Products
5340 Handicap Aids
5350 Medical Monitoring Equipment
5380 Health related optics (incl. glasses, lenses)
5399 Other Medical/Health (NEC)
5410 Hospitals/Clinics/Primary Care
5420 Managed care (including PPO/PPM)
5429 Other Healthcare Facilities
5430 Emergency Services/Ambulance
5440 Hospital & Other Institutional Management
5499 Other Medical/Health Services
5510 Pharmaceutical Research
5520 Pharmaceutical Production
5530 Pharmaceutical Services
5540 Pharmaceutical Equipment
5550 Pharmaceuticals/Fine Chemicals (non-biotech)
5599 Other Pharmaceutical NEC
2320 Medical/Health
2325 Scientific
3700 Analytical & Scientific Instrumentation
4100 Human Biotechnology
4200 Agricultural/Animal Biotechnology
4300 Industrial Biotechnology
4400 Biosensors
4500 Biotech Related Research & Production Equipment
4600 Biotech Related Research & Other Services
4900 Other Biotechnology Related
5100 Medical Diagnostics
5200 Medical Therapeutics
5300 Medical Health Related Products
5400 Medical Health Services
5500 Pharmaceuticals
4000 Biotechnology and Pharmacology
5000 Medical/Health Related
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Appendix 2: Industry Coding for SDC Platinum Rounds
J IndustryDescription I IndCode
Advertising and Public Relations services
Agricultural/Animal Biotechnology biotech
Airlines and Aviation Related services
Analytical & Scientific Instrumentation device
Biochemical Products biotech
Biosensors device
Biosensors for Industrial Applications device
Biosensors for Medical Diagnostic Applications device
Biotech laser and optronic applications device
Biotech Processes for Enhanced Oil Recovery/Mining biotech
Biotech Processes for Food Industrial Applications biotech
Biotech Processes for Pollution/Toxic Waste Contrl biotech
Biotech Related Analytical Instruments & Apparatus device
Biotech Related Animal Health & Nutrition Products biotech
Biotech Related Commodity Chemicals biotech
Biotech Related Fine Chemicals (NOT Pharmaceuts.) biotech
Biotech Related Food Diagnostics diagnostics
Biotech Related Food Enzymes and Cultures biotech
Biotech Related Production Equipment device
Biotech Related Research & Other Services services
Biotech Related Research & Production Equipment device
Biotechnology and Pharmacology biotech
Business and Office Services Services
CAD/CAM, CAE.EDA Systems hcit
CAT Scanning device
Chemical and Solid Material Recycling services
Chromatographs & Related Laboratory Equipment device
Communications/Networking Software hcit
Computerized Billing & Accounting Services services
Consulting Services services
Data Processing,Analysis & Input Services services
Database & File Management hcit
Dependent Care (child care/assisted living services
Diagnostic Services services
Diagnostic Test Products & Equipment diagnostics
Display Panels hcit
Disposable Medical Products device
Distributors,Importers and Wholesalers services
DNA/RNA Probes biotech
Drug Delivery & Other Equipment device
Ecommerce Services services
Educational Software hcit
Emergency Services/Ambulance services
Finance/Insurance/Real Estate products hcit
Finance/Insurance/Real Estate Services hcit
Financial Services,0Other services
Genetic Engineering biotech
Genetic. Eng. Microorganisms to raise plant yield biotech
Genetically Engineered Animals biotech
Genetically Engineered Plants biotech
Graphics and Digital Imaging Software hcit
Handicap Aids device
Health & Beauty Aids services
Health related optics (including glasses, lenses) device
Holding Companies services
Hospital & Other Institutional Management services
Hospitals/Clinics/Primary Care services
Human Biotechnology biotech
Immune Response Effectors (interferons,vaccines) biotech
In Vitro Monoclonal Antibody Diagnostics biotech
In Vivo Monoclonal Antibody Diagnostics/Imaging biotech
Industrial Biotechnology biotech
Insurance Related services
Integrated Turnkey Systems and Solutions hcit
Internet Access Services and Service Providers hcit
Internet/Web Design and programming services hcit
Laser Related device
Local Area Networks (incl. voice/data PBX systems) hcit
Long Term Care/Home Care/Elder Care services
i IndustryDescription
Managed care (including PPO/PPM)
Media Related Services
Medical Diagnostic Biotechnology Products
Medical Diagnostics
Medical Health Related Products
Medical Health Services
Medical Imaging
Medical Monitoring Equipment
Medical Therapeutics
Medical/Health
Medical/Health Info/Content
Medical/Health Related
Medical/Health Services
Medical/Health Software
Mobile Communications, Pagers & Cellular Radio
Nuclear Imaging
Other Analytical & Scientific Instrumentation
Other Animal Related Biotechnology
Other Animal Related Biotechnology
Other Biochemical Products
Other Biosensors
Other Biotech Process for Food/Industrial Products
Other Biotech Research & Production Equipment
Other Biotechnology Related
Other Biotechnology Services
Other Computer Services
Other Electronics Related (including keyboards)
Other Healthcare Facilities
Other Industrial Biotechnology
Other Measuring Devices
Other Medical Diagnostic Biotechnology
Other Medical Diagnostics
Other Medical Imaging
Other Medical/Health (NEC)
Other Medical/Health Services
Other Pharmaceutical NEC
Other Plant Related Biotechnology
Other Telephone Related
Other Therapeutic (including defibrillators)
Other Therapeutic Biotechnology
Other Therapeutic Proteins (incl. hormones & TPA)
Pacemakers & Artificial Organs
Packaging Products & Systems
Pharmaceutical Equipment
Pharmaceutical Production
Pharmaceutical Research
Pharmaceutical Services
Pharmaceuticals
Pharmaceuticals/Fine Chemicals (non-biotech)
Printing & Binding
Publishing
Publishing Services
Pure & Contract Biotechnology Research
Scientific
Scientific Info/Content
Scientific Products
Scientific Software
Security/Alarm/Sensors
Software Services
Surgical Instrumentation & Equipment
Surgical lasers (including laser delivery fibers)
Systems Software
Therapeutic Biotechnology Products
Therapeutic Monoclonal Antibodies
Therapeutic Services
Ultra Sound Imaging
Water Treatment Equipment & Waste Disposal Systems
X-Rays
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I IndCode
services
hcit
diagnostics
diagnostics
device
services
device
device
biotech
biotech
hcit
diagnostics
services
hcit
hcit
device
device
biotech
biotech
biotech
device
biotech
device
biotech
services
hcit
hcit
services
biotech
device
diagnostics
diagnostics
device
NEC
services
biotech
biotech
hcit
device
biotech
biotech
device
services
device
device
biotech
services
biotech
biotech
services
services
services
biotech
hcit
hcit
hcit
hcit
hcit
services
device
device
hcit
device
biotech
services
device
services
device
Appendix 3: IPO Counts averaged for years 3-6 from vintage year
num ipos avg year 3-6
1980 723.8
1981 660.5
1982 579.3
1983 503.5
1984 308.3
1985 242.5
1986 313.0
1987 418.8
1988 517.8
1989 567.5
1990 651.5
1991 645.3
1992 589.3
1993 574.0
1994 462.0
1995 332.5
1996 264.8
1997 154.3
1998 105.8
1999 134.3
From Ritter
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